Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven medulloblastoma. - Yao, Yue‐Liang; Wang, Yan‐Xia; Yang, Fei‐Cheng; Wang, Chuan; Mao, Min; Gai, Qu‐Jing; He, Jiang; Qin, Yan; Yao, Xiao‐Xue; Lan, Xi; Zhu, Jiang; Lu, Hui‐Min; et al. (CNS Neuroscience & Therapeutics, 2022)